Neocalcidol Soft Capsule 1 Microgram (Alfacalcidol)

Adult dose

For chronic kidney disease and osteoporosis, alfacalcidol should be administered orally at 0.5 to 1 μg once daily. For hypoparathyroidism and other conditions related to vitamin D metabolism disorders, it should be administered orally at 1 to 4 μg once daily.

Child dose

For osteoporosis, alfacalcidol should be administered orally at 0.01 to 0.03 μg per kg of body weight once daily. For other conditions, it should be administered orally at 0.05 to 0.1 μg per kg of body weight once daily.

This drug should not be taken by people with abnormally high levels of calcium and phosphorus in the blood. It can be particularly dangerous for patients with hypercalcemia, hyperphosphatemia, or hypermagnesemia. Patients with high alkalinity in the blood (high pH) should also avoid this medication. It should not be used if there are symptoms of vitamin D toxicity or if there is an allergy to any ingredient in this medication. During treatment, do not take magnesium-containing products, vitamin D or its derivatives, calcium-containing preparations, and specific diuretics at the same time. The risk of hypercalcemia or other side effects can increase when used with these medications. Women who are breastfeeding should avoid this medication as its safety has not been established, and if it must be taken, it is advisable to stop breastfeeding. Women who are pregnant or may become pregnant should discuss thoroughly with their doctor before taking it due to risks to the fetus. Children and the elderly, people with a history of kidney stones, and those taking certain medications should consult with a healthcare professional before taking it as dosage adjustments may be necessary. During treatment, regular checks of serum calcium levels and kidney function should be conducted, and if abnormalities are found, medication should be stopped immediately, and healthcare professionals should be consulted. Overdosage can lead to various side effects such as gastrointestinal disturbances, neurological abnormalities, impaired kidney function, liver dysfunction, skin rash, vision abnormalities, etc., so caution is necessary. If symptoms of hypercalcemia appear during treatment, medication should be stopped immediately and appropriate treatment should be sought. This medication should be kept out of reach of children, stored in a cool and dry place away from direct sunlight. It is important not to transfer it to other containers and to keep it in its original packaging to prevent misuse or deterioration.

Serious side effects

Hives, severe swelling, tightness in the chest, difficulty breathing, cold sweat, paleness, severe rash with high fever, blisters, skin peeling, mucosal pain in the mouth/eyes, shortness of breath or difficulty breathing, asthma attack, respiratory disturbance with cough and fever, yellowing of the skin or eyes (jaundice), severe overall fatigue, sudden and severe headache, thunderclap headache, seizures, confusion of consciousness, vision abnormalities, paralysis, and urination issues.

Mild side effects

• Loss of appetite
• nausea
• vomiting
• diarrhea
• constipation
• stomach pain
• discomfort in the upper abdomen
• abdominal bloating
• dyspepsia
• thirst

This medication is sensitive to light and should be stored in a dark container that does not allow light in. It is also best kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its efficacy and safety.

Appearance

An orange oval soft capsule containing a colorless or transparent oily substance.

Package unit

30 capsules/bottle, 100 capsules/bottle